Reply to the letter comment of Su Boon Yong MD, PhD and colleagues to: Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE− 2 study

This publication has 8 references indexed in Scilit:

• Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE−2 study
  Pharmacological Research, 2024
• Strategies for minimizing muscle loss during use of incretin‐mimetic drugs for treatment of obesity
  Obesity Reviews, 2024
• AWARE A novel web application to rapidly assess cardiovascular risk in type 2 diabetes mellitus
  Acta Diabetologica, 2023
• Once‐weekly semaglutide use in patients with type 2 diabetes: Real‐world data from the SURE Italy observational study
  Diabetes, Obesity and Metabolism, 2023
• Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01)
  Frontiers in Endocrinology, 2023
• 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
  European Heart Journal, 2019
• Liraglutide and cardiovascular outcomes in a real world type 2 diabetes cohort
  Pharmacological Research, 2018
• Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial
  The Lancet Diabetes & Endocrinology, 2018